Sheel Biotech Ltd (NSE SME)

User profile picture

Sheel Biotech

September 30, 2025 – October 3, 2025

Price ₹59 - ₹63
GMP Rumors * ₹0
Lot size 2000
Allotment Oct 6, 2025
Listing Oct 8, 2025


Sheel Biotech Lot(s) Distribution

Category Lot(s) Qty Amount Reserved
INDIVIDUAL 2 4000 252000 0
sHNI 3 6000 378000 0
bHNI 8 16000 1008000 0

Sheel Biotech Reservation

Category Shares Offered %
Total 0 100%

Sheel Biotech About

Sheel Biotech IPO Details as per DRHP
Issue Size54,00,000 shares
(aggregating up to ₹34.02 Cr)
Fresh Issue54,00,000 shares
(aggregating up to ₹34.02 Cr)
Issue TypeBookbuilding IPO
Listing AtNSE SME
Share Holding Pre Issue1,49,52,550 shares
Share Holding Post Issue2,03,52,550 shares
Reserved for Market Maker2,72,000 shares
(aggregating up to ₹1.71 Cr)
Sheel Biotech IPO Reservation
Investor CategoryShares Offered
QIB Shares OfferedNot more than 50% of the Net Issue
Retail Shares OfferedNot less than 35% of the Net Issue
NII Shares OfferedNot less than 15% of the Net Issue
Key Performance Indicators (KPI)
Details will be added soon.
Company Financials In Crores
PeriodMay 2024Mar 2024Mar 2023Mar 2022
Assets105.98105.9593.8993.08
Income3.9992.5580.1971.07
Profit0.4810.515.084.51
Net Worth73.2172.7363.5459.75
Reserves69.0768.5859.455.61
Borrowing25.2223.5419.1723.58
 
Company Overview

Incorporated: November 1991

Business Focus: Biotechnology, floriculture, greenhouses, and organic projects

Core Offerings: Tissue culture plants, hydroponics, greenhouses, horticultural turnkey projects, landscaping, organic adoption & certification, FPO management, and skill development programs

Certifications: ISO 9001:2015, 14001:2015, 45001:2018

R&D Recognition: Department of Biotechnology (DBT) and Department of Science & Technology (DST), Govt. of India

Objects of the Issue The Company Sheel Biotech IPO proposes to utilise the Net Proceeds from the Issue towards the following objects: The primary objective is to meet the company's Capital Expenditure requirement, for which Rs. 9.12 crores is allocated. A significant portion of the proceeds, Rs. 15.88 crores, will be used to meet the Working Capital requirements of the company. Additionally, a portion of the funds will be used for General Corporate Purposes.

Strength

Expertise in Biotechnology & Greenhouse Management – Skilled in advanced tissue culture, organic farming, and modern horticultural technologies.

Diverse Product & Service Portfolio – Ranging from planting material and turnkey greenhouse projects to organic certification, FPOs, and training.

Sustainability & Recognition – Eco-friendly practices with government-recognized R&D and international certifications for quality, safety, and environment.

Weakness

High Precision Requirement in Tissue Culture – Any lapse in sterilization, storage, or temperature control can cause contamination and heavy losses.

Tender Dependency in Organic Farming – Revenue is significantly reliant on securing government tenders, making the segment vulnerable to policy or tendering changes.

Operational Risk in Process Management – Even minor negligence in tissue culture techniques could disrupt the entire production cycle.

Sheel Biotech Lead Manager(s)

Sheel Biotech Address

Sheel Biotech Ltd.
8 Balaji Estates
, 2nd Floor, Block-C, Guru Ravidas Marg
Kalkaji
South Delhi, New Delhi, 110019
Phone: +91 88511 - 8980
Email: compliance@sheelbiotech.com
Website: http://www.sheelbiotech.com/

Sheel Biotech Registrar

Skyline Financial Services Private Ltd
Address: Skyline Financial Services Private Ltd D-153A, 1st Floor, Okhla Industrial Area, Phase-I, New Delhi -110020

Sheel Biotech Reviewers

Reviewer Recommendation File